Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Biochem Pharmacol. 2017 Oct 20;149:174–185. doi: 10.1016/j.bcp.2017.10.007

Figure 2. 5-FU-resistant HCT116 cells exhibit partial resistance to oxaliplatin.

Figure 2

HCT116 and 5-FU-resistant HCT116 cells were treated with oxaliplatin (1–100 μM) for 48 h. (A) MTT reduction in both HCT116 and 5-FU-resistant HCT116 cells treated with oxaliplatin. (B) Necrotic cell death determined by LDH release in HCT116 and 5-FU-resistant HCT116 cells treated with oxaliplatin. Data represent mean ± SEM. n = 5–8 per group. *P < 0.05 vs HCT116 CTL; #P < 0.05 vs. 5-FU-resistant HCT116 CTL; †P < 0.05 (based on two-way ANOVA corrected with Tukey’s post-hoc test). Oxal: oxaliplatin.